欧洲前列腺癌发病率与死亡率及筛查启示:基于人群研究
该基于人群研究分析了26个欧洲国家1980-2017年前列腺癌发病与死亡数据,发现发病率国家间差异最大达20倍且随时间变化,而死亡率差异仅5倍且多数国家稳步下降,提示存在过度诊断,未来筛查需谨慎设计以减少过度诊断危害。
要点
- 前列腺癌发病率国家间差异高达20倍,死亡率差异仅5倍。
- 发病率变化与PSA检测时间趋势平行,提示过度诊断。
- 未来筛查实施需精心设计,重点减少过度诊断危害。
核心结论
- 前列腺癌流行病学特征提示过度诊断随时间及人群变化,支持未来筛查需谨慎设计以减少过度诊断危害。
研究设计与样本
- 基于人群研究,纳入26个欧洲国家(其中19个欧盟国家)1980-2017年男性发病数据及1980-2020年死亡数据。
主要发现
- 2000年代中期国家间发病率差异最大,范围从46(乌克兰)至336(法国)每10万男性。
- 多数国家死亡率稳步下降,国家间差异较小,最高与最低发病率差从1985年89.6至2007年385.8每10万男性。
- 死亡率国家间差异从1983年23.7至2006年35.6每10万男性,发病率年龄曲线呈倒U形而死亡率随年龄递增。
临床怎么用
- 全科医生应了解前列腺癌过度诊断风险,参与筛查决策时强调个体化权衡获益与危害。
局限性
- 结果为生态学研究性质,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide a baseline comparative assessment of the main epidemiological features of prostate cancer in European populations as background for the proposed EU screening initiatives. DESIGN: Population based study. SETTING: 26 European countries, 19 in the EU, 1980-2017. National or subnational incidence data were extracted from population based cancer registries from the International Agency for Research on Cancer's Global Cancer Observatory, and mortality data from the World Health Organization. POPULATION: Men aged 35-84 years from 26 eligible countries. RESULTS: Over the past decades, incidence rates for prostate cancer varied markedly in both magnitude and rate of change, in parallel with temporal variations in prostate specific antigen testing. The variation in incidence across countries was largest around the mid-2000s, with rates spanning from 46 (Ukraine) to 336 (France) per 100 000 men. Thereafter, incidence started to decline in several countries, but with the latest rates nevertheless remaining raised and increasing again in the most recent quinquennium in several countries. Mortality rates during 1980-2020 were much lower and less variable than incidence rates, with steady declines in most countries and lesser temporal differences between countries. Overall, the up to 20-fold variation in prostate cancer incidence contrasts with a corresponding fivefold variation in mortality. Also, the inverse U-shape of the age specific curves for incidence contrasted with the mortality pattern, which increased progressively with age. The difference between the highest and lowest incidence rates across countries ranged from 89.6 per 100 000 men in 1985 to 385.8 per 100 000 men in 2007, while mortality rates across countries ranged from 23.7 per 100 000 men in 1983 to 35.6 per 100 000 men in 2006. CONCLUSIONS: The epidemiological features of prostate cancer presented here are indicative of overdiagnosis varying over time and across populations. Although the results are ecological in nature and must be interpreted with caution, they do support previous recommendations that any future implementation of prostate cancer screening must be carefully designed with an emphasis on minimising the harms of overdiagnosis.
引用
- Vaccarella S, Li M, Bray F, et al. Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study. BMJ. 2024. PMID: 39231588. doi:10.1136/bmj-2023-077738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。